Published: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 551 to 575 of 881

Sort by

Guidance programme: Technology appraisal guidanceRemove Guidance programme: Technology appraisal guidance filter

Published guidance, NICE advice and quality standards
Title	Reference number	Published	Last updated
Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs	TA543	3 October 2018	3 October 2018
Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia	TA541	19 September 2018	19 September 2018
Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours	TA539	29 August 2018	29 August 2018
Dinutuximab beta for treating neuroblastoma	TA538	22 August 2018	22 August 2018
Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine	TA535	8 August 2018	8 August 2018
Alectinib for untreated ALK-positive advanced non-small-cell lung cancer	TA536	8 August 2018	8 August 2018
Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs	TA537	8 August 2018	8 August 2018
Dupilumab for treating moderate to severe atopic dermatitis	TA534	1 August 2018	1 August 2018
Ocrelizumab for treating relapsing–remitting multiple sclerosis	TA533	25 July 2018	25 July 2018
Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer	TA531	18 July 2018	18 July 2018
Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy	TA530	4 July 2018	4 July 2018
Beta interferons and glatiramer acetate for treating multiple sclerosis	TA527	27 June 2018	27 June 2018
Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease	TA217	23 March 2011	20 June 2018
Arsenic trioxide for treating acute promyelocytic leukaemia	TA526	13 June 2018	13 June 2018
Guselkumab for treating moderate to severe plaque psoriasis	TA521	13 June 2018	13 June 2018
Midostaurin for untreated acute myeloid leukaemia	TA523	13 June 2018	13 June 2018
Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma	TA524	13 June 2018	13 June 2018
Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy	TA525	13 June 2018	13 June 2018
Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy	TA520	16 May 2018	16 May 2018
Tocilizumab for treating giant cell arteritis	TA518	18 April 2018	18 April 2018
Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen	TA515	28 March 2018	28 March 2018
Cabozantinib for treating medullary thyroid cancer	TA516	28 March 2018	28 March 2018
Brodalumab for treating moderate to severe plaque psoriasis	TA511	21 March 2018	21 March 2018
Tivozanib for treating advanced renal cell carcinoma	TA512	21 March 2018	21 March 2018
Obinutuzumab for untreated advanced follicular lymphoma	TA513	21 March 2018	21 March 2018

Results per page

10
25
50
All